MT-251 Study for Healthy Volunteers
This study is testing a new drug called MT-251 for the first time in people. It aims to understand how safe MT-251 is, how well your body tolerates it, and how your body processes it. Researchers will also look at how your immune system responds to MT-251. This study is open to healthy volunteers between 19 and 55 years old. For women, you must be past menopause or have had surgery that prevents you from having children. The main goal is to track any side effects, both serious and not serious, for up to 14 days after you receive the drug. This information will help guide future development of MT-251. The current recruitment status for this study is unclear.
- Study design
- This is a Phase 1, randomized, double-blind, placebo-controlled study involving about 70 healthy participants. It will test single and multiple doses of MT-251.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be monitored for non-serious and serious side effects for up to 14 days after receiving the dose.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A First-in-Human Single and Multiple Ascending Dose Study of MT-251
At a glance
Conditions
NCT07423299
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mirador Clinical Department
San Diego, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Subjects with non-SAEs and SAESUp to 14 days post dose.
Incidence of adverse events, clinically significant laboratory abnormalities, clinically significant electrocardiogram, vital signs, and physical examination abnormalities.